You just read:

Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma

News provided by

Amgen

Aug 30, 2017, 16:18 ET